Nkarta, Inc.

NKTX · Nasdaq · SIC 2834: Pharmaceutical Preparations
99
SEC Filings

Business Summary

PART I . Overview We are a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies. Our company was founded on the belief that engineered NK cell therapies can transform the lives of patients by offering therapies that are clinically meaningful, broadly accessible and unencumbered by the safety concerns often associated with other cell therapy approaches. Our lead pipeline program is NKX019, a chimeric antig...

Next Earnings

Q2 FY2026 — expected 2026-08-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionNKTXdiscussed_in_filing Cybersecurity
topic_mentionNKTXdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-252025-12-310001787400-26-000006EDGAR89K words
2025-03-262024-12-310000950170-25-045262EDGAR—
2024-03-212023-12-310000950170-24-034735EDGAR—
2023-03-162022-12-310000950170-23-008523EDGAR—
2022-03-172021-12-310000950170-22-004095EDGAR—
2021-03-252020-12-310001564590-21-015517EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001193125-25-274304EDGAR64K words
2025-08-122025-06-300001193125-25-178964EDGAR—
2025-05-142025-03-310000950170-25-071455EDGAR—
2024-11-072024-09-300000950170-24-123395EDGAR—
2024-08-132024-06-300000950170-24-096186EDGAR—
2024-05-092024-03-310000950170-24-056980EDGAR—
2023-11-092023-09-300000950170-23-062091EDGAR—
2023-08-102023-06-300000950170-23-040953EDGAR—
2023-05-112023-03-310000950170-23-021277EDGAR—
2022-11-092022-09-300000950170-22-023845EDGAR—
2022-08-112022-06-300000950170-22-016892EDGAR—
2022-05-122022-03-310000950170-22-009693EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-260001787400-26-000008EDGAR1K words
2026-03-250001787400-26-000005EDGAR—
2025-11-100001193125-25-274261EDGAR—
2025-08-120001193125-25-178949EDGAR—
2025-06-060000950170-25-082717EDGAR—
2025-05-140000950170-25-071399EDGAR—
2025-03-260000950170-25-045231EDGAR—
2024-11-070000950170-24-123340EDGAR—
2024-08-130000950170-24-096163EDGAR—
2024-07-160000950170-24-083761EDGAR—

99 total filings indexed. 71 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001787400
TickerNKTX
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 7a0ec4d73ecd5cca6238893e8acd293f96f35ec5ba677594ce4084f34089bfaa
parent: 03699c2db467555e0f4704520267c08ae5016abc53f1db4024710f02bd5346f0
content hash: ee4fbdbbce1fd5161c91610cb840ba0f12e80d7294fe5624d192d1e33defcf51
signed: 2026-04-13T04:46:31.325Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf